** Shares of Australia's 4DMedical 4DX.AX rise as much as 14.7% to A$0.545, hitting their highest since early December 2024
** Medical technology-focussed firm says it has received clearance from the U.S. Food and Drug Administration for its IQ-UIP™ product
** The product is an advanced AI-driven lung diagnostic tool designed for the diagnosis of usual interstitial pneumonia
** Stock fell 32.9% in 2024
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))